Subscribe To
Atara biotherapeutics, inc. (atra) q3 2023 earnings call transcript
Atara biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2023 Results Conference Call November 1, 2023 9:00 AM ET ...
November 4, 2023, 11:45 am
Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting
– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encourag...
November 3, 2023, 8:05 pm
Sensei biotherapeutics appoints stephanie krebs, ms, mba, as chief business officer
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) — Sensei biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stag...
November 1, 2023, 11:30 am
Down -50.77% in 4 weeks, here's why you should you buy the dip in arcutis biotherapeutics, inc. (arqt)
Arcutis biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaus...
November 1, 2023, 11:21 am
Zymeworks announces participation in upcoming investor conferences
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel,...
November 1, 2023, 8:30 am
Arcutis biotherapeutics, inc. (arqt) loses -51.27% in 4 weeks, here's why a trend reversal may be around the corner
The heavy selling pressure might have exhausted for Arcutis biotherapeutics, Inc. (ARQT) as it is techn...
October 31, 2023, 11:21 am
Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance biotherapeutics, Inc. (NASDAQ: IOVA), a b...
October 31, 2023, 9:05 am
Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage...
October 25, 2023, 9:05 am
Why is sonnet biotherapeutics (sonn) stock down 33% today?
Sonnet biotherapeutics (NASDAQ: SONN ) stock is falling on Wednesday after the biotechnology company r...
October 25, 2023, 8:42 am
Iovance biotherapeutics: testing shareholders' patience
Iovance biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment o...
October 22, 2023, 9:12 am
Arcutis biotherapeutics shares sink on $100m stock sale
Arcutis biotherapeutics Inc shares slid more than 18% in pre-market trading on Friday after the early c...
October 20, 2023, 9:13 am
Arcutis announces pricing of $100 million public offering
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) — Arcutis biotherapeutics, Inc. (Nasdaq: ARQ...
October 20, 2023, 3:45 am
Iovance biotherapeutics: good trade setup created by the fda delay gets even better
Iovance biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better...
October 19, 2023, 2:35 pm
Excision biotherapeutics announces presentation of interim clinical data for ebt-101 in latent hiv at upcoming european society of gene and cell therapy (esgct) 2023 annual congress
SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) — Excision biotherapeutics, Inc., a clinical-stage biot...
October 19, 2023, 11:50 am
Zymeworks to host third quarter 2023 results conference call
VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel,...
October 17, 2023, 8:30 am
Synlogic announces reverse stock split
CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non...
September 27, 2023, 4:30 pm
Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting
SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance biotherapeutics, Inc. (NASDAQ: IOVA), a ...
September 27, 2023, 4:01 pm
Iovance biotherapeutics: navigates regulatory delays with strategic finesse (rating upgrade)
Iovance biotherapeutics shows promise in T-cell therapies for solid tumors despite FDA delays; robust f...
September 18, 2023, 10:43 pm
Why shares of iovance biotherapeutics jumped monday
Iovance's lead therapy lifileucel still has a chance at an early approval to treat advanced melanoma. Lifileucel is also being tested to treat several...
September 18, 2023, 12:46 pm
Why iovance biotherapeutics stock rocketed 13% higher today
At first glance, the latest regulatory news is a setback. However, there were more than a few silver linings in this development....
September 15, 2023, 4:20 pm